Saama and Pfizer Expand Agreement to Integrate AI-Driven Data Solutions Across R&D Portfolio
Portfolio Pulse from Benzinga Newsdesk
Saama and Pfizer have expanded their partnership with a multi-year agreement to integrate AI-driven data solutions across Pfizer's R&D portfolio. This agreement builds on their 2020 collaboration which resulted in the development of Smart Data Quality (SDQ), aimed at accelerating clinical research by streamlining data review processes.
February 12, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's expanded agreement with Saama to use AI for accelerating clinical research could enhance R&D efficiency and potentially speed up drug development.
The expanded partnership with Saama to integrate AI-driven data solutions across Pfizer's R&D portfolio is likely to streamline and accelerate data review processes. This could lead to faster clinical research, potentially speeding up drug development timelines and improving R&D efficiency. Given the strategic nature of the partnership and its focus on core R&D processes, this agreement is highly relevant and important for Pfizer.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90